Completed PHASE2 INTERVENTIONAL 2-arm NCT00517829

Docetaxel+Oxali+/-Cetux Met Gastric/GEJ

Phase II Trial of Docetaxel Plus Oxaliplatin (DOCOX) With or Without Cetuximab in Patients With Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma

Sponsor: Eli Lilly and Company

Conditions Gastric Cancer Adenocarcinoma Metastatic

Interventions Docetaxel cetuximab oxaliplatin

Updated 7 times since 2017 Last updated: Oct 14, 2016 Started: Jul 31, 2007 Primary completion: Apr 30, 2012 Completion: Apr 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00517829, this PHASE2 trial focuses on Gastric Cancer Adenocarcinoma Metastatic and remains completed. Sponsored by Eli Lilly and Company, it has been updated 7 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Nov 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Nov 2019 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company
Sanofi
US Oncology Research

Data source: US Oncology Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amarillo, United States , Arlington, United States , Austin, United States , Beaumont, United States , Bedford, United States , Birmingham, United States , Boardman, United States , Chicago, United States , Columbia, United States , Dallas, United States and 33 more locations